ArticlePleura and peritoneum2026
Textbook oncologic outcomes after cytoreductive surgery and HIPEC for colorectal peritoneal metastases: a single-centre cohort analysis.
Article in Pleura and peritoneum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment for selected patients with colorectal peritoneal metastases (CPM). The recently proposed concept of textbook oncologic outcomes (TOO) offers a composite benchmark for surgical quality, but its applicability and prognostic relevance in CPM remain largely unexplored. Methods: We conducted a retrospective single-centre analysis of all patients undergoing CRS and HIPEC for CPM between 2007 and 2025. Primary endpoint was overall survival (OS); secondary analyses assessed individual TOO components and associated factors. Results: Eighty-four patients met inclusion criteria (age 54.1 ± 12.1 years, PCI 5.8 ± 4.5). CC0 resection was achieved in 88.1 %, severe postoperative complications occurred in 34.5 %, and reoperation was required in 20.2 % of patients. Ninety-day mortality was 1.2 %. Complete TOO was achieved in 14.3 % of patients as only 31/84 were recommended adjuvant chemotherapy. Median OS was 39.2 months. Absence of reoperation (p=0.02), and negative lymph node status (p=0.04) were significantly associated with improved OS. Conclusions: TOO was achieved in <50 % of patients, mainly due to the absence of adjuvant chemotherapy. Absence of reoperation was associated with survival, suggesting its validity as quality indicator. Refinement of TOO definitions, incorporating patient-centred recovery measures, may improve their applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.